Yung Lyou, MD, PhD, discusses the key takeaways from the phase 3 ENZAMET trial in metastatic prostate cancer.
Yung Lyou, MD, PhD
Advertisement
Articles by Yung Lyou, MD, PhD
Yung Lyou, MD, PhD, discusses the efficacy of androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.
Yung Lyou, MD, PhD, discusses emerging biomarkers in prostate cancer.
Yung Lyou, MD, PhD, discusses optimal sequencing with apalutamide in prostate cancer.
Advertisement
Latest Updated Articles
Dr. Lyou on the Efficacy of ADT Plus Docetaxel in High-Volume mHSPCPublished: August 30th 2021 | Updated:
Dr. Lyou on Sequencing Apalutamide in Prostate CancerPublished: July 16th 2021 | Updated:
Dr. Lyou on Key Takeaways from the ENZAMET Trial in Metastatic Prostate CancerPublished: August 31st 2021 | Updated:
Dr. Lyou on Emerging Biomarkers in Prostate CancerPublished: July 19th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5